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OBJECTIVES:This study compares socio-demographic characteristics, comorbidity
profiles, and functional impairments affecting adults diagnosed with attention
deficit hyperactive disorder (ADHD) to their non-ADHD counterparts in Europe.
METHODS: Data are from the 2011 National Health and Wellness Survey (NHWS),
conducted annually by Kantar Health. The NHWS has been administered annually
since 2002 among samples of adults drawn from an international consumer panel
recruited and maintained by Lightspeed research. Data reported in this study were
gathered between September and December 2011 in Germany, UK, France, Spain,
and Italy. T-tests of means and proportions were used to test for significant differ-
ences between adults with diagnosed ADHD and a non-ADHD control group from
the NHWS sample. All differences reported below were significant at the p0.05
level. RESULTS: A total of 235 NHWS participants reported having received a diag-
nosis for ADHD from a physician. Diagnosed ADHD respondents were more fre-
quently male (59% vs. 49%) and less likely married (38% vs. 50%) than non-ADHD
controls. Diagnosed ADHD respondents were more likely to report sleep difficulties
(67% vs. 25%), anxiety (61% vs. 16%), depression (59% vs. 12%), or headaches (57% vs.
39%). Likelihoods of a general practitioner visit (77% vs. 65%), an emergency room
visit (34% vs. 11%), or a hospitalization (32% vs. 8%) within the past 6 months were
greater among diagnosed ADHD respondents than non-ADHD controls. Diagnosed
ADHD respondents were also less likely employed full-time (27% vs. 39%), and
more likely to report health-related work productivity loss (55% vs. 20%).
CONCLUSIONS: Adults from 5 western European nations with self-reported diag-
noses of ADHD reported higher rates of comorbidity with a variety of mental,
emotional, or physical disorders, higher rates of health resource utilization, lower
rates of full-time employment and higher rates of health-related work productivity
impairment than adults without ADHD.
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OBJECTIVES: To gain insights into the perceived value of alternative treatment
formulations in the management of schizophrenia. METHODS: A search of 75
health technology assessment (HTA) agencies was performed to identify single
technology appraisals published between January 2010 and June 2012 on pharma-
ceutical treatments for schizophrenia. Per agency, only the most recent appraisal
for each drug identified was selected for analysis. Reasons for recommendation
and non-recommendation were evaluated in-depth for each appraisal. RESULTS:
In total 32 appraisals (9 rejections; 23 recommendations) were identified across 12
agencies. These appraisals represent the most recent decision made for a specific
drug by a particular agency. Overall 5 different formulations were assessed includ-
ing long-acting depot formulations (14 appraisals), oral immediate release (IR) tab-
lets (13), orodispersible tablets (3), an oral long release (LR) tablet (1), and an oral
solution (1). Non-recommendations were only identified for depot, oral IR and oral
LR formulations. In most cases high drug costs, lack of head-to-head and long-term
clinical data were the main reasons for rejection. Submissions resulting in a rec-
ommendation were identified for all but the LR tablet formulation. Reasons for
recommendation included proven clinical non-inferiority to direct comparators,
cost savings and a better dosing schedule. As most new formulations did not offer
a benefit in efficacy, decisions were weighted on cost. In all long-acting formulation
submissions, manufacturers stated that use of the drug would lead to improved
patient compliance. Only one submission (HAS) provided data to support this
claim. SMC and AWMSG were the only agencies to criticise the absence of compli-
ance data. CONCLUSIONS: A higher drug price for a new formulation is only war-
ranted when clear clinical advantages are presented. This is particularly evident
for long-acting formulations where a higher price, on grounds of improved com-
pliance, is not favourable. There was very little disparity between agencies in their
decision making approach.
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OBJECTIVES: To put the apparent rise of the administrative prevalence of atten-
tion-deficit/hyperactivity disorder (ADHD) in the region of Nordbaden in South-
western Germany into context by analyzing the most frequently diagnosed mental
health problems in this population. METHODS: The complete claims database of
the organization of physicians registered with statutory health insurance [SHI]
(Kassenaerztliche Vereinigung, KV) in Nordbaden/Germany was available for analy-
sis, covering the total regional population enrolled in SHI (2.2 million). The data-
set for years 2003 to 2009 was reorganized as to allow patient-centered evaluation.
RESULTS:Most frequently diagnosed mental health problems in 2009 were depres-
sive episodes (ICD-10 code F32.9), with an overall administrative 12-months prev-
alence rate of 8.3%; unspecified somatoform disorders (F45.9), 4.8%; harmful use of
tobacco (F17.1), 3.4%; neurasthenia (F48.0), 2.3%; and adjustment disorders (F43.2),
2.2%. Uncomplicated hyperkinetic disorder (HKD, F90.0) was the number one rea-
son for contacts with health care providers in children (age group 6-12 years, 7.2%)
and adolescents (13-17 years, 3.7%), reported more than twice as often as the next
frequently diagnosed mental health problems, namely various developmental,
speech, and adjustment disorders. In preschoolers, speech and developmental
problems were diagnosed more frequently than HKD (1.0%). From 2003 to 2009, the
administrative prevalence of ADHD (HKD/F90.0 and hyperkinetic conduct disorder,
HKCD/F90.1, combined) increased by 79%, i.e., from 0.53% in 2003 to 0.95% (overall;
6-12 years, 8.0%; 13-17 years, 4.2%) in 2009. Notwithstanding lower absolute num-
bers, ADHD prevalence in adults increased more than fourfold, from 0.04% (2003) to
0.17% (2009). CONCLUSIONS: By 2009, ADHD represented the leading mental
health related cause of service utilization among children and adolescents in Nor-
dbaden. The present analysis underscores the need for in-depth research address-
ing the quality, cost, cost effectiveness, and broader economic implications of
health and social service provision for children, adolescents, and adults with a
diagnosis of ADHD.
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OBJECTIVES: To gain insight into the reimbursement landscape of pharmacologi-
cal treatments against alcohol dependency.METHODS:We have conducted a man-
ual search of 75 Health Technology Assessment (HTA) agencies’ websites for alco-
hol-related assessments published worldwide since 2001. All reports were
categorized by HTA type, scope and outcome. Using a standardized set of categor-
ical criteria, we investigated the recommendations for pharmacological treat-
ments of alcohol disorders to identify common patterns in key decision drivers in
this therapeutic area. RESULTS:We identified a total of 81 HTA reports dedicated to
treatment of alcohol-related disorders. By the time of this study, 70% of the HTA
reports were completed and therefore included into the analysis. The 57 published
reports comprised 13 Single Technology Assessments (STA), 1 Multiple Technology
Assessment (MTA), 6 Clinical Guidelines (CG), 14 Public Health Reviews, 6 Proce-
dure / Intervention Assessments and 17 Literature Reviews. While 40 HTAs were
mostly focused on public health impact of alcohol disorders and general organiza-
tion of treatment, pharmacological treatment of alcohol dependence was assessed
in 17 reports (within the scope of STAs, MTAs or CGs). Medications assessed the
most were acamprosate and naltrexone. The vast majority of agencies have issued
positive recommendations for these drugs, assuming they are used as second-line
options and/or in combination with psychosocial interventions. Naltrexone was
rejected by several agencies (e.g. AHTAPol, SIGN), partially justified by high risks/
major adverse events and poor data supporting the benefits of the drug.
CONCLUSIONS:Alcohol-related disorders attract attention of HTA agencies world-
wide. Current research however shows that only a limited number of reports assess
medications. One of the main decision drivers for approvals was the mere neces-
sity of a pharmacological treatment which emphasizes a high unmet need in the
management of alcohol dependence.
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OBJECTIVES: Research has been conducted on parent and patient preferences for
ADHD medication, yet medication attributes that may influence the physician’s
prescribing behavior are not well understood. The aim of this study was to identify
the primary attributes of ADHD medications that influence the prescribing behav-
ior of physicians treating ADHD, and to explore country variation in these factors
across Europe.METHODS:A retrospective chart review of ADHD patients aged 6-17
was conducted in six European countries. Charts of 779 patients diagnosed be-
tween 2004-2007 were reviewed by 361 physicians. Physicians were asked to select
three main medication attributes influencing their selection of ADHD medication
for newly treated patients. The 19 total attributes were grouped by the researchers
into 6 domains: efficacy, duration of action (DOA), convenient dosing, prior expe-
rience, safety, and cost/other. Descriptive statistics were used to compare prescrib-
ing behavior by medication attributes, and chi-square tests assessed country
differences. RESULTS: Efficacy (33%), convenience (19.6%) and DOA (17.3%) were
the 3 most frequently selected attributes that influenced ADHD medication selec-
tion, followed by prior experience (13.3%), safety (11.4%) and cost/other (5.3%). DOA
was particularly important in France (23.0%) relative to its importance in the Neth-
erlands (13.9%), while convenient dosing was equally important across all coun-
tries except Italy (11.6%). Medication cost was significantly more important in the
Netherlands (13.9%) and Spain (8.0%) relative to France and the UK (1.6% and 2.3%,
respectively; p0.0001); while safety was rated highest among physicians in Italy
(22.7%) relative to those in the Netherlands (4.8%; p0.0001). CONCLUSIONS: Effi-
cacy, convenience, and duration were the most frequently selected medication attributes
influencing physician prescribing behavior; but there were differences in selected attri-
butes by country. Further research is needed to better understand the environmental
context influencing physician prescription behavior, and the impact that market-level
factors may have on treatment choices and patient outcomes in Europe.
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OBJECTIVES: A model assessing sequential olfactory testing and dopamine trans-
porter (DAT) imaging for screening pre-motor Parkinson’s Disease (PD) was
adapted to a European setting with German cost and health utility data.METHODS:
PD Associated Risk Study (PARS) data were used to parameterize screening efficacy.
Screening strategies in persons 1) in a general population, 2) with a relative with PD,
3) with LRRK2 genotype, and 4) with REM sleep disorder were evaluated. PD prev-
alence per 100 at screening was 0.5, 2, 10 and 20 for these groups. Olfactory test and
DAT costs were €11 and €1500, respectively. We assumed disease modifying (DM)
therapy was available that slowed disease progression by 20% at a cost of €30,000.
Economic value was measured in net monetary benefits (NMB), valuing a quality-
adjusted life-year at €50,000. RESULTS: Screening sensitivity and specificity were
64% and 99%, respectively. 13.4% had positive results on the olfactory test and also
took the DAT. NMB for the four groups was €-169, €269, €2,603, and €5,521, indicat-
ing that screening has positive economic value in persons with a close relative with
PD, persons with LRRK2 genotype, and persons with REM sleep disorder. Screen-
ing value was positively correlated with rate of progression from preclinical to
clinical PD, efficacy of DM therapy, and QALY monetization. Screening value was
negatively correlated with costs of false positives, screening cost, age at onset,
Hoehn and Yahr stage at which the unscreened diagnosis is made, and cost of DM
therapy. CONCLUSIONS: Screening for early PD may be a cost-effective strategy for
certain risk groups.
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OBJECTIVES: New diagnostic approaches, including molecular profiling, have im-
proved the ability to establish accurate diagnoses of hematologic cancers, but have
also increased the complexity of test ordering, information integration and inter-
pretation. This study examined the role of specialty and other laboratory providers,
the types of diagnostic tests provided for patients with suspected hematologic
cancers, and subsequent health care costs. METHODS: Patients with bone marrow
biopsies and suspected hematologic cancer/condition (2005-2011) were identified
from claims data from a large US health plan. Included patients had 6 pre- &
3-months post-biopsy health plan coverage. Lab tests in the 30 days post-biopsy
were identified. Patient cohorts were based upon laboratories performing marrow
morphologic assessment/directing testing sequence: Genoptix (GX, a specialty he-
matology-testing laboratory); large commercial laboratories (LL), other laboratories
(OL); academic labs were excluded. Diagnostic/treatment medical costs (per-pa-
tient-per-month) during the 30-days & 1 year post-biopsy were examined (ANOVA).
RESULTS: Of 30,393 patients with suspected hematologic malignancy/condition,
94.25% had marrow morphology reviewed. OL patients were slightly younger (58.19
OL vs. , 59.88 GX, 59.39 LL, P0.001). More flow cytometry was done at GX (96.68%)
vs 87.68% in LL and 69.78% in OL. Cytogenetics/FISH analysis rates were: 95.96% GX,
80.78% LL, 51.68% OL. Use of molecular diagnostics was less common (26.03% in GX,
14.27% in LL and 9.31% in OL). 1-year PPPM costs were $4487 GX, $4325 LL, and $5407
OL (P0.001)); costs PPPM excluding the testing period were $2132 GX, $2686 LL, and
$3341 OL (P0.001). CONCLUSIONS: Frequency of diagnostic tests in the 30-days
post-biopsy varied, with complex tests conducted more frequently in the hematol-
ogy specialty laboratory. However, disease-related costs with the specialty labora-
tory were lower than costs for some laboratories with lower use of these tests.
Further exploration of the impact of alternative diagnostic testing approaches on
costs and clinical outcomes is warranted.
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OBJECTIVES: Due to high cost and limited availability of dual-energy x-ray absorp-
tiometry (DXA), 77 percent of high risk population remains undiagnosed and there-
fore untreated for osteoporosis. To cope up with current scenario, pre-screening
tools have become apparent as pragmatic tool for extensive screening of osteopo-
rosis. Use of such tools would help health care professionals to make better use of
bone densitometry and to cut billions of dollars cost associated with DXA. This
study attempts to evaluate possible reasons that pose hindrance in implementa-
tion of such tools despite of reliability and cost effective nature of such tools.
METHODS: Using convenience sampling method, a pre-validated questionnaire
was used to conduct a cross-sectional survey among health care professionals in
Malaysia. 5 endocrinologists, 10 orthopedic specialists, 25 medical officers, 30 hos-
pital pharmacists participated from Hospital Pulau Penang while 33 community
pharmacists and 27 general practitioners from Penang participated in survey(total
130). RESULTS: There was no statistically significant difference regarding knowl-
edge of pre-screening tools among health care professionals belonging to different
specialties. Although, 77% of participants have heard about pre-screening tools but
only 53 % were able to identify the purpose of such tools. Out of list of 8 pre-
screening tools, majority 36 % identified SCORE followed by MOST (22 %) as pre-
screening tools while other tools were not identified. Only 5 % of participants have
used such tools while 94 % showed willingness to use such tools and to encourage
patients to undergo screening by such tools. Majority 61 % preferred leaflets/ bro-
chures to gain information regarding availability and utility of such tools while
least 13 % preferred continuous education programs. CONCLUSIONS: Proper
awareness regarding availability and utility of such tools would not only help to
improve patient’s quality of life also it would help to reduce global economic bur-
den associated with osteoporosis.
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OBJECTIVES: Few data exists on high cardiovascular risk (HCVR) prevalence within
a primary prevention population. The goal of the study was to assess HCVR distri-
bution, according to the European SCORE risk assessment scale, in France in high-
risk primary care patients not treated with lipid-lowering drug. METHODS: This
observational study was conducted over a week on a representative sample of
French general practitioners (GP). All consulting primary care men/women 50/60
y, with at least one other CVR factor (smoking, high blood pressure (HBP), type 2
diabetes, HDL-c0.40 g/L), not treated for dyslipidemia were included in the study.
GP filled-in an on line questionnaire that enabled SCORE calculation. RESULTS:GPs
(n1147) included 9049 patients (mean age: 68 y; male: 57%; LDLc1.3 g/L: 57%;
smoking: 21%; HBP: 44%; type 2 diabetes: 21% HDL-c0.4 g/L: 16%). According to
SCORE, HCVR prevalence reached 50% in total population (male: 49%, female: 51%).
50% of HCVR men/women were older than 72.4/78.8 y. HCVR patients were older
by 7.7/6.8 y for male/female (p 0.01) than non-HCVR patients. Other significantly
more frequent characteristics in high CVR population are: HDL0.6 g/L (38%), un-
treated or uncontrolled HBP (53%) and left ventricular hypertrophy (8%). Obesity is
less frequent (15%) in high CVR population. Highest HCVR prevalence was observed
in the Mediterranean population (54%), and lowest (47%) in the Northeast popula-
tion (p 0.01). Adjustment by age and gender reduces regional disparities (52% vs
48%).CONCLUSIONS:Half consulting primary care patients aged50/60 y for men/
women with at least 1 risk factor on top of age and no lipid-lowering treatment are
at HCVR according to SCORE risk equation. Assessing cardiovascular risk with risk
equations appears particularly useful in this group of patients. Besides age, which
has the strongest impact on risk estimation, other RF may be screened to improve
HCVR management.
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OBJECTIVES: To systematically review the current clinical and cost-effectiveness
literature of third-generation, implantable left ventricular assist devices (LVADs)
for people with end-stage heart failure (ESHF). METHODS: Three implantable,
third-generation LVADs were identified as available in the EU. A systematic litera-
ture review was conducted of published and unpublished cost-effectiveness and
clinical data (comparative studies) in the ESHF population, since their inception till
April 2012, using a number of medical databases. RESULTS:One relevant economic
evaluation and four comparative clinical studies (1 vs. virtual control arm & 3 vs.
older-generation LVADs) met the inclusion criteria. Therapy success defined as
survival LVAD or explant to receive a heart transplant or for recovery, occurred in
approx. 92.0% of patients with third-generation LVADs and 90.1% of control pa-
tients (second-generation LVAD) in a 6-months period. The 1-year survival of pa-
tients who were implanted with third-generation LVADs ranged from 82% to 91%.
The most frequently reported adverse events were arrhythmias, bleeding, infec-
tion, respiratory and renal failure, right heart failure, and stroke. One included
study evaluates the cost-effectiveness of the implantable, third-generation LVADs
as destination therapy for patients with ESHF as compared to patients on medical
management in the UK. Results showed that at 5ys LVADs had an additional cost of
about £20,500 per patient and QALY gain of 1.05, giving an incremental cost per
QALY of £19 500, which is below the commonly adopted threshold of £25,000 per
QALY. However, this finding seems unreliable due to controversial assumptions.
CONCLUSIONS:Despite the poor methodological quality of included studies, third-
generation of implantable LVADs seems beneficial due to improving survival, ther-
apy success and functional status. Adverse events serious concern. No prospective
controlled data are available as bridge to recovery, nor destination therapy. There
is an urgent need for additional, reliable cost-effectiveness studies evaluating
third-generation pumps versus previous generations of LVADs.
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OBJECTIVES: To assess the clinical effectiveness of extracorporeal photopheresis
(ECP) in the treatment of acute or chronic steroid-refractory graft versus host dis-
ease (GvHD). METHODS: Clinical effectiveness of the analysed intervention was
evaluated in accordance with the principles of systematic review based on the
Cochrane Collaboration guidelines (Cochrane Reviewer’s Handbook) and the guide-
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